Redirecting to Aptorum Group Announces Submission of Clinica

December 22, 2020 healthcare
Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies for the treatment of a variety of medical conditions including infectious diseases, announced that the company, through its wholly owned subsidiary Aptorum International Limited, has submitted a Clinical Trial Application (CTA) with the Public Health Agency of Canada (Health Canada) to conduct a Phase 1 clinical trial of ALS-4, an orally administered small molecule drug for the treatment of infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA). Pending Health Canada’s approval, the Phase 1 trial is designed to test the safety, tolerability and pharmacokinetics of ALS-4 in healthy volunteers.

Related Keywords

Canada , Clark Cheng , Aptorum Group Form , Aptorum Group Or , Public Health Agency Of Canada , Daptorum Group , Aptorum Group Limited Nasdaq , Aptorum International , Health Canada , Aptorum Group Acticule , Regulatory News , Group Limited , Euronext Paris , Aptorum International Limited , Clinical Trial Application , Public Health Agency , Methicillin Resistant Staphylococcus , Pending Health Canada , Chief Medical Officer , Executive Director , Aptorum Group Limited , Private Securities Litigation Reform Act , French Autorit , Des March , Regulations Delegated , கனடா , கிளார்க் செங் , ஆரோக்கியம் கனடா , ஒழுங்குமுறை செய்தி , குழு வரையறுக்கப்பட்டவை , மருத்துவ சோதனை விண்ணப்பம் , நிலுவையில் உள்ளது ஆரோக்கியம் கனடா , தலைமை மருத்துவ அதிகாரி , நிர்வாகி இயக்குனர் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , தேஸ் அணிவகுப்பு ,